Skip to main
DCGO

DocGo (DCGO) Stock Forecast & Price Target

DocGo (DCGO) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 25%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

DocGo is positioned for future growth through their enterprise deal with an online pharmacy and the acquisition of Hicuity Health, which has a profitable virtual care business. While revenue declined in 2Q26, they exceeded our estimates for gross margins and have added resources, such as debt capital, to increase liquidity. With a majority of revenue generated in the United States, there is potential for further expansion into other markets to drive even more growth.

Bears say

DocGo is facing several headwinds, including slower-than-expected cost cuts impacting profitability and potential delays in the licensing process. While the company's recent acquisition of Hicuity Health brought in significant revenue, there are concerns about the sustainability of this growth. Additionally, the company's narrowed revenue guidance and lowered adjusted EBITDA outlook for FY26 also raises concerns about their ability to achieve long-term profitability. There is also the risk of COVID-related uncertainty and the possibility of decreased revenue once testing contracts and vaccine programs wind down. Overall, DocGo's negative outlook is based on these concerns and the company's need to overcome these challenges in order to achieve sustained growth and profitability.

DocGo (DCGO) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 25% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DocGo and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DocGo (DCGO) Forecast

Analysts have given DocGo (DCGO) a Buy based on their latest research and market trends.

According to 4 analysts, DocGo (DCGO) has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DocGo (DCGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.